Clearbridge Investments LLC Trims Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Clearbridge Investments LLC decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 4.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 943,378 shares of the biopharmaceutical company’s stock after selling 43,810 shares during the period. Clearbridge Investments LLC owned 1.60% of Agios Pharmaceuticals worth $51,990,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Amundi Pioneer Asset Management Inc. boosted its position in shares of Agios Pharmaceuticals by 3,306.0% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 143,050 shares of the biopharmaceutical company’s stock valued at $9,648,000 after acquiring an additional 138,850 shares during the period. Envestnet Asset Management Inc. bought a new position in shares of Agios Pharmaceuticals in the first quarter valued at approximately $206,000. Principal Financial Group Inc. boosted its position in shares of Agios Pharmaceuticals by 15.5% in the first quarter. Principal Financial Group Inc. now owns 106,223 shares of the biopharmaceutical company’s stock valued at $5,486,000 after acquiring an additional 14,222 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Agios Pharmaceuticals by 22.0% in the first quarter. Teacher Retirement System of Texas now owns 6,948 shares of the biopharmaceutical company’s stock valued at $359,000 after acquiring an additional 1,251 shares during the period. Finally, UBS Group AG boosted its position in shares of Agios Pharmaceuticals by 333.2% in the first quarter. UBS Group AG now owns 26,337 shares of the biopharmaceutical company’s stock valued at $1,360,000 after acquiring an additional 37,632 shares during the period.

Shares of AGIO opened at $45.53 on Thursday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $32.47 and a fifty-two week high of $62.15. The firm has a 50 day moving average price of $45.20 and a 200-day moving average price of $51.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.39) by ($0.05). Equities research analysts expect that Agios Pharmaceuticals, Inc. will post -3.9 earnings per share for the current year.

A number of equities analysts have recently commented on the stock. HC Wainwright raised their price objective on shares of Agios Pharmaceuticals from $88.00 to $93.00 and gave the company a “buy” rating in a research report on Friday, July 30th. The Goldman Sachs Group lowered shares of Agios Pharmaceuticals from a “neutral” rating to a “sell” rating and cut their price objective for the company from $58.00 to $39.00 in a research report on Friday, July 30th. SVB Leerink started coverage on shares of Agios Pharmaceuticals in a research report on Friday, July 30th. They set a “hold” rating and a $50.00 target price for the company. Finally, Raymond James started coverage on shares of Agios Pharmaceuticals in a research report on Wednesday, June 30th. They set a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $63.08.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Featured Article: What is a stock portfolio tracker?

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.